TFFP

TFF Pharmaceuticals, Inc. [TFFP] Stock Forecast

Q: What is TFF Pharmaceuticals, Inc. stock symbol ?

TFF Pharmaceuticals, Inc. is a US stock, located in Austin of Tx and trading under the symbol TFFP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TFFP Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

Does not have any significance market cap ($9.7M)

TFFP has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

TFFP

Top 10 Correlated Stocks

TFFP

In the News

TFFP Financial details

Company Rating

Neutral

Market Cap

9.7M

Income

-21.08M

Revenue

Book val./share

4.04

Cash/share

2.32

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2024

P/E

-12.47

Forward P/E

PEG

2.37

P/S

P/B

21.59

P/C

1.42

P/FCF

-0.75

Quick Ratio

8.83

Current Ratio

9.54

Debt / Equity

0.01

LT Debt / Equity

EPS (TTM)

-12.56

EPS next Y

EPS next Q

EPS this Y

-55.27%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-13.36%

SMA20

-50%

SMA50

-33.33%

SMA100

-42.86%

Inst Own

30.55%

Inst Trans

1.73%

ROA

-159%

ROE

-145%

ROC

-1.74%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

3.85-21.25

52W High

-84.33%

52W Low

+9.67%

RSI

Rel Volume

0.51

Avg Volume

29.45K

Volume

15.16K

Perf Week

-19.16%

Perf Month

-60.07%

Perf Quarter

-58.24%

Perf Half Y

-64.04%

Beta

1.288

Volatility

0.28%, 1.87%

Prev Close

1.53%

Price

3.29

Change

-1.5%

TFFP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0.41
Net income per share	-42.55	-22.57	-31.21	-26.49	-11.85
Operating cash flow per share	-40.61	-20.34	-29.77	-22.8	-8.95
Free cash flow per share	-40.61	-21.69	-30.64	-24.09	-9
Cash per share	101.72	43.21	34.04	13.85	3.06
Book value per share	100.09	45.7	39.02	19.08	5.34
Tangible book value per share	100.09	45.7	39.02	19.08	5.34
Share holders equity per share	100.09	45.7	39.02	19.08	5.34
Interest debt per share	0	0	0	0.14	0.06
Market cap	36.94M	292.49M	220.16M	31.48M	12.58M
Enterprise value	8.85M	257.19M	186.37M	15.06M	7.22M
P/E ratio	-3.14	-15.86	-7.1	-0.99	-0.59
Price to sales ratio	0	0	0	0	17.15
POCF ratio	-3.29	-17.6	-7.45	-1.15	-0.78
PFCF ratio	-3.29	-16.51	-7.24	-1.09	-0.78
P/B Ratio	1.34	7.83	5.68	1.38	1.32
PTB ratio	1.34	7.83	5.68	1.38	1.32
EV to sales	0	0	0	0	9.84
Enterprise value over EBITDA	-0.74	-13.76	-5.88	-0.48	-0.33
EV to operating cash flow	-0.79	-15.48	-6.31	-0.55	-0.45
EV to free cash flow	-0.79	-14.52	-6.13	-0.52	-0.45
Earnings yield	-0.32	-0.06	-0.14	-1.01	-1.69
Free cash flow yield	-0.3	-0.06	-0.14	-0.92	-1.28
Debt to equity	0	0	0	0.01	0.01
Debt to assets	0	0	0	0.01	0.01
Net debt to EBITDA	2.34	1.89	1.07	0.52	0.24
Current ratio	71.08	28.41	19.81	16.83	3.13
Interest coverage	0	0	0	1.19K	0
Income quality	0.94	0.89	0.95	0.86	0.75
Dividend Yield	0.02	0	0	0	0
Payout ratio	-0.07	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	14.4
Research and developement to revenue	0	0	0	0	15.75
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.07	0.03	0.06	0.01
Capex to revenue	0	0	0	0	-0.13
Capex to depreciation	0	0	-7.79	-4	-0.19
Stock based compensation to revenue	0	0	0	0	3.99
Graham number	309.56	152.35	165.53	106.64	37.72
ROIC	-0.43	-0.5	-0.82	-1.37	-2.33
Return on tangible assets	-0.4	-0.48	-0.76	-1.32	-1.77
Graham Net	96.13	41.59	34.02	12.93	1.87
Working capital	28.78M	36.24M	36.88M	17.89M	5.16M
Tangible asset value	27.64M	37.34M	38.74M	22.88M	9.57M
Net current asset value	27.64M	36.24M	36.88M	17.78M	5.13M
Invested capital	0	0	0	0.01	0.01
Average receivables	0	0	1.3M	1.39M	310.18K
Average payables	419.64K	854.18K	1.4M	1.21M	939.02K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	215.78
Days payables outstanding	0	0	4.89K	864.6	696.21
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	1.69
Payables turnover	0	0	0.07	0.42	0.52
Inventory turnover	0	0	0	0	0
ROE	-0.43	-0.49	-0.8	-1.39	-2.22
Capex per share	0	-1.35	-0.87	-1.29	-0.05

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-5.1	-4.76	-3.47	-2.32	-2.01
Operating cash flow per share	-5.32	-3.02	-3.08	-1.58	-1.78
Free cash flow per share	-5.42	-3.02	-3.1	-1.59	-1.8
Cash per share	11.47	8.44	5.29	5.13	2.32
Book value per share	15.8	11.43	8.48	7.21	4.04
Tangible book value per share	15.8	11.43	8.48	7.21	4.04
Share holders equity per share	15.8	11.43	8.48	7.21	4.04
Interest debt per share	0.12	0.01	0.11	0.07	0.05
Market cap	38M	24.8M	17.01M	16.6M	16.61M
Enterprise value	21.58M	12.76M	9.5M	7.01M	11.25M
P/E ratio	-1.29	-0.9	-0.85	-0.94	-0.87
Price to sales ratio	0	0	0	0	0
POCF ratio	-4.93	-5.68	-3.82	-5.53	-3.94
PFCF ratio	-4.85	-5.68	-3.79	-5.51	-3.9
P/B Ratio	1.66	1.5	1.39	1.21	1.74
PTB ratio	1.66	1.5	1.39	1.21	1.74
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.97	-1.8	-1.94	-1.63	-2.1
EV to operating cash flow	-2.8	-2.92	-2.13	-2.34	-2.67
EV to free cash flow	-2.75	-2.92	-2.11	-2.33	-2.64
Earnings yield	-0.19	-0.28	-0.3	-0.27	-0.29
Free cash flow yield	-0.21	-0.18	-0.26	-0.18	-0.26
Debt to equity	0.01	0.01	0.01	0.01	0.01
Debt to assets	0.01	0.01	0.01	0.01	0.01
Net debt to EBITDA	2.26	1.7	1.53	2.23	1
Current ratio	16.83	8.85	7.75	9.54	3.13
Interest coverage	615.12	44.78	0	0	0
Income quality	1.04	0.62	0.89	0.68	0.88
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0	0.01	0	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.17	0	-0.29	-0.1	-0.36
Stock based compensation to revenue	0	0	0	0	0
Graham number	42.57	34.99	25.73	19.42	13.53
ROIC	-0.32	-0.41	-0.4	-0.31	-0.56
Return on tangible assets	-0.31	-0.38	-0.37	-0.3	-0.4
Graham Net	10.71	7.38	4.55	4.64	1.41
Working capital	17.89M	12.38M	8.2M	9.75M	5.16M
Tangible asset value	22.88M	16.54M	12.28M	13.69M	9.57M
Net current asset value	17.78M	12.29M	8.13M	9.7M	5.13M
Invested capital	0.01	0.01	0.01	0.01	0.01
Average receivables	1.47M	187.64K	236.47K	322.83K	397.67K
Average payables	1.28M	1.13M	1.18M	995.14K	970.86K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	684.51	982.4	733.68	707.29	660.15
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.13	0.09	0.12	0.13	0.14
Inventory turnover	0	0	0	0	0
ROE	-0.32	-0.42	-0.41	-0.32	-0.5
Capex per share	-0.1	0	-0.02	-0.01	-0.02

TFFP Frequently Asked Questions

What is TFF Pharmaceuticals, Inc. stock symbol ?

TFF Pharmaceuticals, Inc. is a US stock , located in Austin of Tx and trading under the symbol TFFP

What is TFF Pharmaceuticals, Inc. stock quote today ?

TFF Pharmaceuticals, Inc. stock price is $3.29 today.

Is TFF Pharmaceuticals, Inc. stock public?

Yes, TFF Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 29.45K
Market Capitalization 9.7M
Employee 19
CEO Dr. Harlan F. Weisman
Headquarters Austin,TX,US
IPO Date 2019-10-25
Website https://www.tffpharma.com

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.